Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival

Thrombosis Research

Volumn 116, Issue 1, 2005, Pages 15-24

  Nilsson, Gunnar ^a   Astermark, Jan ^a   Lethagen, Stefan ^a   Vernersson, Einar ^a   Berntorp, Erik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Antithrombin; Blood coagulation disorders; Global haemostatic tests; Intensive care; Mortality; Protein C

Indexed keywords

ANTITHROMBIN; PROTEIN C;

ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CRITICAL ILLNESS; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SAMPLE SIZE; STATISTICAL MODEL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT;

EID: 17444406333     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.09.020     Document Type: Article

References (34)

1. G. Nilsson, J. Astermark, S. Lethagen, E. Vernersson, and E. Berntorp The prognostic value of global haemostatic tests in the intensive care unit setting Acta Anaesthesiol. Scand. 46 2002 1062 1067
2. S. Bredbacka, M. Blombäck, B. Wiman, and H. Pelzer Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects Acta Anaesthesiol. Scand. 37 1993 125 130
3. M. Yu, A. Nardella, and L. Pechet Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis Crit. Care Med. 28 2000 1777 1780
4. E.F. Mammen Disseminated intravascular coagulation (DIC) Clin. Lab. Sci. 13 2000 239 245
5. M. Levi, E. de Jonge, and J. Meijers The diagnosis of disseminated intravascular coagulation Blood Rev. 16 2002 217 223
6. W.A. Knaus, E.A. Draper, D.P. Wagner, and J.E. Zimmerman APACHE II: a severity of disease classification system Crit. Care Med. 13 1985 818 829
7. P.A. Owren, and K. Aas Control of dicumarol therapy and quantitative determination of prothrombin and proconvertin Scand. J. Clin. Lab. Invest. 3 1951 201 208
8. EQUALIS, Uppsala, Sweden (2004, January 7). Home page. Retrieved March 24, 2004 from the World Wide Web: http://www.equalis.se/INR/EQUALIS INR-kalibrering ver. 6.1.xls, page 2: Conversion table INR-PK%.
9. C. Esmon The protein C pathway Crit. Care Med. 28 2000 S44 S48 [Suppl.]
10. S. Kanji, J.W. Devlin, K.A. Piekos, and E. Racine Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis Pharmacotherapy 21 2001 1389 1402
11. F. Fourrier, C. Chopin, J. Goudemand, S. Hendrycx, C. Caron, and A. Rime Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies Chest 101 1992 816 823
12. J.A. Lorente, L.J. Garcia-Frade, L. Landin, R. de Pablo, C. Torrado, and E. Renes Time course of hemostatic abnormalities in sepsis and its relation to outcome Chest 103 1993 1536 1542
13. J. Boldt, M. Papsdorf, A. Rothe, B. Kumle, and S. Piper Changes of the hemostatic network in critically ill patients-is there a difference between sepsis, trauma, and neurosurgery patients? Crit. Care Med. 28 2000 445 450
14. D. Powars, R. Larsen, J. Johnson, T. Hulbert, T. Sun, and M.J. Patch Epidemic meningococcemia and purpura fulminans with induced protein C deficiency Clin. Infect. Dis. 17 1993 254 261
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Crit. Care Med. 20 1992 864 874
16. M.M. Levy, M.F. Fink, J.C. Marshall, E. Abraham, D. Angus, D. Cook for the International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference Crit. Care Med. 31 2003 1250 1256
17. L. Bajzar, M.E. Nesheim, and P.B. Tracy The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent Blood 88 1996 2093 2100
18. L. Bajzar Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway Arterioscler. Thromb. Vasc. Biol. 20 2000 2511 2518
19. C.J. Fisher, and S.B. Yan Protein C levels as a prognostic indicator of outcome in sepsis and related diseases Crit. Care Med. 28 2000 S49 S56 [Suppl.]
20. S.B. Yan, J.D. Helterbrand, D.L. Hartman, T.J. Wright, and G.R. Bernard Low levels of protein C are associated with poor outcome in severe sepsis Chest 120 2001 915 922
21. F. Fourrier, C. Chopin, J.J. Huart, I. Runge, C. Caron, and J. Goudemand Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation Chest 104 1993 882 888
22. C. Waydhas, D. Nast-Kolb, C. Gippner-Steppert, A. Trupka, C. Pfundstein, and L. Schweiberer High-dose antithrombin III treatment of severely injured patients: results of a prospective study J. Trauma 45 1998 931 940
23. B.L. Warren, A. Eid, P. Singer, S.S. Pillay, P. Carl, I. Novak for the KyberSept Trial Study Group High-dose antithrombin III in severe sepsis: a randomized controlled trial JAMA 286 2001 1869 1878
24. D. Rublee, S.M. Opal, W. Schramm, H.O. Keinecke, and S. Knaub Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023] Crit. Care 6 2002 349 356
25. O.P. Smith, B. White, D. Vaughan, M. Rafferty, L. Claffey, and B. Lyons Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans Lancet 350 1997 1590 1593
26. C.E. Ettingshausen, A. Veldmann, T. Beeg, W. Schneider, G. Jager, and W. Kreuz Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans Semin. Thromb. Hemost. 25 1999 537 541
27. B. White, W. Livingstone, C. Murphy, A. Hodgson, M. Rafferty, and O.P. Smith An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia Blood 96 2000 3719 3724
28. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, A. Lopez-Rodriguez for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group Efficacy and safety of recombinant human activated protein C for severe sepsis NEJM 344 2001 699 709
29. E.W. Ely, D.C. Angus, M.D. Williams, B. Bates, R. Qualy, and G.R. Bernard Drotrecogin alfa (activated) treatment of older patients with severe sepsis Clin. Infect. Dis. 37 2003 187 195
30. S.B. Yan, and J.F. Dhainaut Activated protein C versus protein C in severe sepsis Crit. Care Med. 29 2001 S69 S74 [Suppl.]
31. S.N. Faust, M. Levin, O.B. Harrison, R.D. Goldin, M.S. Lockhart, and S. Kondaveeti Dysfunction of endothelial protein C activation in severe meningococcal sepsis NEJM 345 2001 408 416
32. Ö. Çakir, O. Ayyildiz, A. Oruc, and N. Eren A young adult with coronary artery and jugular vein thrombosis: a case report of combined protein S and protein C deficiency Heart Vessels 17 2002 74 76
33. I.Y. Tiong, M.L. Alkotob, and S. Ghaffari Protein C deficiency manifesting as an acute myocardial infarction and ischaemic stroke Heart 89 2003 E7
34. M.A. Peterman, and W.C. Roberts Syndrome of protein C deficiency and anterior wall acute myocardial infarction at a young age from a single coronary occlusion with otherwise normal coronary arteries Am. J. Cardiol. 92 2003 768 770